April Sparks in Ophthalmology: Surge in Financing, Patents, and Collaborations

　　【Pharmaceutical Network Industry DynamicsIn the field of ophthalmic drugs, Chinese pharmaceutical companies have been accelerating their strategic layout. It is reported that significant progress has recently been made in multiple areas within China's ophthalmology sector, including medical devices and drug development, with major advancements such as multi-million-dollar financing, patent licensing, and a surge in industry-academia-research collaborations.
 

　　Product
 

On April 17, Haixi Pharma announced that the company's innovative drug project HXP056 had initiated the recruitment of Chinese patients with wet age-related macular degeneration (wAMD) in early July 2025. Currently, all patient recruitment for the single ascending dose (SAD) and multiple ascending dose (MAD) phases of the Phase I clinical trial has been completed. After four weeks of continuous dosing, the dose-limiting toxicity (DLT) evaluation and pharmacokinetic (PK) data collection have also been finalized.
 

On April 7, Haohai Biotech announced that the multifocal aspheric intraocular lens product of its wholly-owned subsidiary, Henan Universe Artificial Lens Co., Ltd., had received the Medical Device Registration Certificate issued by the National Medical Products Administration. The product is suitable for vision correction in aphakic eyes of adult cataract patients, with the aim of improving near, intermediate, and far vision while reducing dependence on glasses.
 

　　Cooperation
 

On April 10, China Eye Valley and Airdoc held a signing and unveiling ceremony to officially establish the China Eye Valley & Airdoc AI Photobiomodulation Research Institute. The institute aims to promote the high-quality development of myopia prevention and control, support the implementation of national strategic goals for myopia prevention and control, and will focus on the deep integration of artificial intelligence and photobiomodulation (PBM) technology.
 

On April 10, Lansheng Medical and Zhenfu Medical signed a strategic cooperation agreement. According to the announcement, Lansheng Medical will rely on its nationwide channel layout and clinical operation capabilities to continuously promote the implementation of high-quality ophthalmic technologies in China; while Zhenfu Medical will focus on the research and development and clinical transformation of technology in the field of dry eye diagnosis and treatment.
 

On April 2, Sapaias announced that the company signed a "Technology Transfer (Patent Rights) Contract" with the Eye Hospital of Wenzhou Medical University and Professor Xiangtian Zhou, acquiring 10 core patents and related rights for "a method of treating myopia using SPAS-26021" for 71 million yuan plus subsequent sales royalties.
 

　　Financing
 

News on April 20: FemtoMarch Medical announced the completion of nearly 100 million yuan in angel round financing. The funds will be used for product technology iteration and upgrades, clinical trials, animal experiments, and more. Following this round of financing, while ensuring the ultra-high performance and quality of top-tier medical equipment, the company will accelerate the registration and clinical trials of femtosecond refractive products to obtain medical device registration certificates both in China and internationally as soon as possible. At the same time, it will expedite the research and development of other ophthalmic diagnosis and treatment products to further enhance the refractive industry chain.
 

April 8th update: Moptim announced the completion of a nearly RMB100-million Series B financing round. The proceeds from this round will be used for the iteration of underlying optical core technologies, expansion of high-end manufacturing capacity, upgrading of AI algorithms, and advancing the scaling deployment of products in grassroots healthcare in China and global markets. Following this financing round, Moptim will focus on three key areas for high-quality development: strengthening core technologies, expanding high-end manufacturing, and globalizing its operations.
 

　　Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.